#South Korea #Seoul #Lunit #Cancer Diagnostics #Precision Oncology

Lunit Presents a Series of Pioneering AI Studies at AACR 2026

Seoul, South Korea—On April 17, 2026, Lunit (KRX:328130), a front-runner in AI solutions for cancer diagnostics and precision oncology, made a significant mark at the American Association for Cancer Research (AACR) Annual Meeting held in San Diego, California. The company showcased six innovative studies that underline its dedication to advancing AI-driven biomarker development and enhancing the understanding of tumor biology.

AI in Cancer Diagnostics

As cancer treatment becomes increasingly personalized, the use of artificial intelligence (AI) is transforming how clinicians approach diagnosis and therapy selection. Lunit’s studies emphasized the role of AI in improving clinical workflows, understanding the spatial features of cancerous tumors, and integrating complex analysis to support clinical decision-making.

One of the standout studies was conducted in partnership with Agilent Technologies and Ajou University Medical Center, where researchers utilized Lunit SCOPE IO and uIHC to analyze a vast dataset of over 25,000 non-small cell lung cancer (NSCLC) samples. Results revealed that tumors exhibiting high levels of c-MET expression corresponded with a drastic reduction in nearby immune cell density, indicating a previously unobserved pattern of immune exclusion that could be crucial for understanding how tumors evade immune responses.

Key Findings and Implications

The implications of these findings are profound. By identifying the potential link between c-MET overexpression and immune evasion, Lunit’s research paves the way for developing more effective treatment combinations involving MET-targeted therapies alongside immunotherapy. This nuanced understanding of tumor biology reflects the need for increasingly sophisticated approaches to cancer treatment.

In addition to the study on c-MET, Lunit presented findings from an exploratory analysis of the phase II MOUNTAINEER trial. This research highlighted the correlation between AI-quantified HER2 expression and patient response to treatment in those with HER2-positive metastatic colorectal cancer receiving tucatinib in combination with trastuzumab. The overall objective response rate reached an impressive 43.4%, with rates as high as 80% for patients with elevated HER2 levels. These results indicate a dose-dependent relationship and underscore the importance of tumor-infiltrating lymphocytes (TIL) in predicting patient outcomes.

The Role of AI in Precision Oncology

Lunit's presentations at AACR 2026 illustrated the increasing complexity involved in biomarker assessments, illustrating how AI can streamline this process and enhance treatment strategies. CEO Brandon Suh stated, “Our AACR presentations reflect how AI is increasingly translating into real-world clinical impact.” The studies not only highlight the AI-driven biomarkers that enhance precision in oncology but also reveal the multifaceted nature of tumor biology that must be considered in treatment plans.

Additional Research Topics

Alongside these pivotal studies, Lunit also displayed several research abstracts that covered a wide range of pioneering topics in AI-driven oncology research. Notable highlights included:

• - AI-based analysis of tumor-infiltrating lymphocytes in NSCLC in collaboration with Dr. David Rimm’s lab at Yale University.
• - AI-driven target discovery for bi-specific antibodies.
• - Research focused on biomarker identification for CD47-targeted therapies.

Concluding Thoughts

Lunit's presence at AACR 2026 was not just about showcasing its research; it demonstrated the practical implications of AI in real-world clinical settings.